RNA Therapeutics Market: By Type (siRNA, ASO, mRNA, saRNA, miRNA, tRNA, Aptamers, Others), By Indication (Oncology, Ophthalmic Disorders, Immunology, Cardiovascular Disorders, Infectious Diseases, Genetic Disorders, CNS Disorders, Others), and Geography  

Purchase Option

$ 4400
$ 6600
$ 8900

RNA Therapeutics Market size was valued at USD 4.93 billion in 2022 and is poised to grow at a CAGR of 17.4% from 2024-2030. RNA Therapeutics market is poised to grow at a significant rate due to an increase in the prevalence of chronic diseases such as cancer and cardiovascular diseases, surge in a number of biopharmaceutical and biotechnology industries, a rise in funding for the development of RNA therapeutics from public and private sectors, promising pipeline drugs, and wide range of applications with RNA therapeutics are the major factors that are driving the growth of the global RNA therapeutics market over the forecast timeframe. Players focusing on innovation of newer products and collaboration strategies to retain market position in the global RNA therapeutics market.

RNA Therapeutics Market Key Developments:
  • In August 2018, US Food and Drug Administration approved the first RNA interference (RNAi) therapeutic, a treatment for polyneuropathy caused by transthyretin (TTR) amyloidosis from Alnylam Pharmaceuticals.  

Global Rna Therapeutics Market Summary

Study Period

2024-2030

Base Year

2023

CAGR

17.40%

Largest Market

North America

Fastest Growing Market

North America
RNA Therapeutics Market Dynamics

Increase in the prevalence of cancer, cardiovascular, and other chronic diseases is a key factor drive the global RNA therapeutics market. According to World Health Organization 2018, approximately 9.6 Mn death occurred due to cancer around the globe. Moreover, according to WHO, approximately 17.9 Mn deaths occurred due to cardiovascular disorders around the globe. In addition, target specificity and selectivity of RNAi therapeutics, more intense product focus versus platform technologies and virtual drug development models are anticipated to propel the global RNA therapeutics market over the forecast years.

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
  • The report covers in-detail insights about the competitor's overview, company share analysis, key market developments, and key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup's details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of the socio-political environment through PESTLE Analysis and competition through Porter's Five Force Analysis in addition to recent technology advancements and innovations in the market

Global Rna Therapeutics Market Segmentation

By Type
  • siRNA
  • ASO
  • mRNA
  • saRNA
  • miRNA
  • tRNA
  • Aptamers
  • Others
By Indication
  • Oncology
  • Ophthalmic Disorders
  • Immunology
  • Cardiovascular Disorders
  • Infectious Diseases
  • Genetic Disorders
  • CNS Disorders
  • Others
By Geography
  • Asia Pacific
  • North America
  • Europe
  • Latin America
  • MEA

Frequently Asked Questions

The RNA Therapeutics Market key players are: Alnylam Pharmaceuticals, Inc. (USA), Genzyme Corporation (USA), Silence Therapeutics PLC (UK), Quark Pharmaceuticals, Inc. (USA), Cenix BioScience GmbH (Germany), Dicerna Pharmaceuticals, Inc. (USA), ISIS pharmaceuticals, Inc. (USA)

The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).

The RNA Therapeutics Market is expected to grow at a CAGR of 17.4% during 2023-29

1.Executive Summary
2.Global RNA Therapeutics Market Introduction 
2.1.Global RNA Therapeutics Market  - Taxonomy
2.2.Global RNA Therapeutics Market  - Definitions
2.2.1.Type 
2.2.2.Indication
2.2.3.Region
3.Global RNA Therapeutics Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Product Landscape
3.6. New Product Launches
3.7. Impact of COVID 19 on Market
4.Global RNA Therapeutics Market Analysis, 2019 - 2023 and Forecast 2024 - 2030
4.1.  Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
4.2.  Year-Over-Year (Y-o-Y) Growth Analysis (%) 
4.3.  Market Opportunity Analysis 
5.Global RNA Therapeutics Market  By Type, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
5.1. siRNA
5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.1.3. Market Opportunity Analysis 
5.2. ASO
5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.2.3. Market Opportunity Analysis 
5.3. mRNA
5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.3.3. Market Opportunity Analysis 
5.4. saRNA
5.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.4.3. Market Opportunity Analysis 
5.5. miRNA
5.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.5.3. Market Opportunity Analysis 
5.6. tRNA
5.6.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.6.3. Market Opportunity Analysis 
5.7. Aptamers
5.7.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.7.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.7.3. Market Opportunity Analysis 
5.8. Others
5.8.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.8.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.8.3. Market Opportunity Analysis 
6.Global RNA Therapeutics Market  By Indication, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
6.1. Oncology
6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.1.3. Market Opportunity Analysis 
6.2. Ophthalmic Disorders
6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.2.3. Market Opportunity Analysis 
6.3. Immunology
6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.3.3. Market Opportunity Analysis 
6.4. Cardiovascular Disorders
6.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.4.3. Market Opportunity Analysis 
6.5. Infectious Diseases
6.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.5.3. Market Opportunity Analysis 
6.6. Genetic Disorders
6.6.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.6.3. Market Opportunity Analysis 
6.7. CNS Disorders
6.7.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.7.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.7.3. Market Opportunity Analysis 
6.8. Others
6.8.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.8.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.8.3. Market Opportunity Analysis 
7.Global RNA Therapeutics Market  By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
7.1. North America
7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.1.3. Market Opportunity Analysis 
7.2. Europe
7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.2.3. Market Opportunity Analysis 
7.3. Asia Pacific (APAC)
7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.3.3. Market Opportunity Analysis 
7.4. Middle East and Africa (MEA)
7.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.4.3. Market Opportunity Analysis 
7.5. Latin America
7.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.5.3. Market Opportunity Analysis 
8.North America RNA Therapeutics Market 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
8.1. Type  Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
8.1.1.siRNA
8.1.2.ASO
8.1.3.mRNA
8.1.4.saRNA
8.1.5.miRNA
8.1.6.tRNA
8.1.7.Aptamers
8.1.8.Others
8.2.  Indication Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
8.2.1.Oncology
8.2.2.Ophthalmic Disorders
8.2.3.Immunology
8.2.4.Cardiovascular Disorders
8.2.5.Infectious Diseases
8.2.6.Genetic Disorders
8.2.7.CNS Disorders
8.2.8.Others
8.3.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
8.3.1.United States of America (USA)
8.3.2.Canada
9.Europe RNA Therapeutics Market 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
9.1. Type  Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.1.1.siRNA
9.1.2.ASO
9.1.3.mRNA
9.1.4.saRNA
9.1.5.miRNA
9.1.6.tRNA
9.1.7.Aptamers
9.1.8.Others
9.2.  Indication Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.2.1.Oncology
9.2.2.Ophthalmic Disorders
9.2.3.Immunology
9.2.4.Cardiovascular Disorders
9.2.5.Infectious Diseases
9.2.6.Genetic Disorders
9.2.7.CNS Disorders
9.2.8.Others
9.3.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.3.1.Germany
9.3.2.France
9.3.3.Italy
9.3.4.United Kingdom (UK)
9.3.5.Spain
10.Asia Pacific (APAC) RNA Therapeutics Market, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
10.1. Type  Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.1.1.siRNA
10.1.2.ASO
10.1.3.mRNA
10.1.4.saRNA
10.1.5.miRNA
10.1.6.tRNA
10.1.7.Aptamers
10.1.8.Others
10.2.  Indication Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.2.1.Oncology
10.2.2.Ophthalmic Disorders
10.2.3.Immunology
10.2.4.Cardiovascular Disorders
10.2.5.Infectious Diseases
10.2.6.Genetic Disorders
10.2.7.CNS Disorders
10.2.8.Others
10.3.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.3.1.China
10.3.2.India
10.3.3.Australia and New Zealand (ANZ)
10.3.4.Japan
10.3.5.Rest of APAC
11.Middle East and Africa (MEA) RNA Therapeutics Market, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
11.1. Type  Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.1.1.siRNA
11.1.2.ASO
11.1.3.mRNA
11.1.4.saRNA
11.1.5.miRNA
11.1.6.tRNA
11.1.7.Aptamers
11.1.8.Others
11.2.  Indication Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.2.1.Oncology
11.2.2.Ophthalmic Disorders
11.2.3.Immunology
11.2.4.Cardiovascular Disorders
11.2.5.Infectious Diseases
11.2.6.Genetic Disorders
11.2.7.CNS Disorders
11.2.8.Others
11.3.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.3.1.GCC Countries
11.3.2.South Africa
11.3.3.Rest of MEA
12.Latin America RNA Therapeutics Market, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
12.1. Type  Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.1.1.siRNA
12.1.2.ASO
12.1.3.mRNA
12.1.4.saRNA
12.1.5.miRNA
12.1.6.tRNA
12.1.7.Aptamers
12.1.8.Others
12.2.  Indication Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.2.1.Oncology
12.2.2.Ophthalmic Disorders
12.2.3.Immunology
12.2.4.Cardiovascular Disorders
12.2.5.Infectious Diseases
12.2.6.Genetic Disorders
12.2.7.CNS Disorders
12.2.8.Others
12.3.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.3.1.Brazil
12.3.2.Mexico
12.3.3.Rest of LA
13. Competition Landscape
13.1.  Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) 
13.2.1.Moderna Therapeutics, Inc.
13.2.2.Alnylam Pharamceuticals, Inc.
13.2.3.Arbutus Biopharma Corp
13.2.4.Sylentis S.A.
13.2.5.Santaris Pharma A/S.
13.2.6.Arrowhead Pharmaceuticals, Inc.
13.2.7.BioNTech AG
13.2.8.Regulus Therapeutics, Inc.
13.2.9.CureVac, AG
13.2.10.Dicerna Pharmaceuticals, AG
13.2.11.Marina Biotech, Inc.
13.2.12.miRagen Therapeutics
13.2.13.Quark Pharmaceuticals, Inc.
13.2.14.Pfizer Inc
14. Research Methodology 
15. Appendix and Abbreviations 
  • Arrowhead Pharmaceuticals, Inc.
  • Alnylam Pharamceuticals, Inc.
  • Arbutus Biopharma Corp
  • BioNTech AG
  • CureVac, AG
  • Dicerna Pharmaceuticals, AG
  • Moderna Therapeutics, Inc.
  • Marina Biotech, Inc.
  • miRagen Therapeutics
  • Pfizer Inc
  • Quark Pharmaceuticals, Inc.
  • Sylentis S.A.
  • Santaris Pharma A/S.

Adjacent Markets